Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Birth-dose reduced-antigen pertussis vaccine in healthy infants
2009-012460-14Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 2010
- Modality
- Vaccines & Immunotherapeutics, Live Biotherapeutic Products → Microbiome Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of GSK-251154, pertussis filamentous haemagglutinin, pneumococcal 13-valent conjugate vaccine and Rotavirus vaccine in pertussis, diphtheria, Tetanus and 5 more (2 arms), sponsored by GSK. Primary endpoints: Immunogenicity with respect to components of the study vaccines, Immunogenicity one month after second primary dose and 2 more. Started Mar 2010; status: completed.
02
Drugs
GSK-251154pertussis filamentous haemagglutininpneumococcal 13-valent conjugate vaccineRotavirus vaccine
03
Conditions
pertussisdiphtheriaTetanushepatitis B (HBV)poliomyelitis
Beyond the preview
Go deeper on 2009-012460-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012460-14.